Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04763655 · ClinicalTrials.gov registry record · NA
Neural Biomarkers of Electroconvulsive Therapy Response
A NA study of Electroconvulsive Therapy Treated Patients, sponsored by Northwell Health.
- Recruiting
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT04763655: Recruiting NA study of Electroconvulsive Therapy Treated Patients, sponsored by Northwell Health.
NCT04763655 is a NA study of Electroconvulsive Therapy Treated Patients that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 75 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04763655, a NA study of Electroconvulsive Therapy Treated Patients, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
In the proposed study, the investigators will utilize resting-state functional MRI (fMRI) and structural MRI-based electrical field modeling to study the effect of electroconvulsive therapy on human neural circuitry. Our study will recruit patients who are beginning treatment with bilateral electroconvulsive therapy (N=75). Our design will be longitudinal where patients will be followed up until their 8th week electroconvulsive therapy clinically. The primary measure of interest will be the slope of clinical change estimated with mixed effect modeling (see Approach). Secondary measures will be the cognitive performance change between baseline and the 8th week electroconvulsive therapy time point.
Primary Outcome
The change of total BPRS score between Week 8 and Baseline divided by baseline (percentage change). The change in the total score which can be between 18-126 (in extreme cases) will be reported.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST clinical and neuropsychological testing
Study Locations (1)
New York
- The Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2025-07-01 |
| Phase | NA |
What NCT04763655 shows while recruiting
NCT04763655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Electroconvulsive Therapy Treated Patients appearing as the primary indexed condition, and to 1 intervention - of which clinical and neuropsychological testing is the first listed.
NCT04763655 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04763655 about?
NCT04763655 is a clinical study titled "Neural Biomarkers of Electroconvulsive Therapy Response". In the proposed study, the investigators will utilize resting-state functional MRI (fMRI) and structural MRI-based electrical field modeling to study the effect of electroconvulsive therapy on human neural circuitry. Our study will recruit patients who are beginning treatment with bilateral electroc...
What is the current status of trial NCT04763655?
This trial is currently recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2020-04-01. Estimated completion is 2025-07-01.
What conditions does trial NCT04763655 study?
This clinical trial studies the following conditions: Electroconvulsive Therapy Treated Patients.
What interventions are being tested in trial NCT04763655?
The interventions under investigation include: clinical and neuropsychological testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04763655?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04763655 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04763655's enrollment target sits among peer trials
75 1069th of 2000 higher than 919 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI